European CHMP does not recommend approval of galcanezumab for prevention of attacks of episodic cluster headache

The CHMP concluded that the results from the main study in the application (n=106; placebo-controlled) did not show clearly that galcanezumab is effective for preventing attacks; therefore it was of the opinion that the benefits did not outweigh its risks.


European Medicines Agency